Skip to content Skip to navigation

FDA approves new MRSA drug dalbavancin

June 5, 2014
by Pamela Tabar, Editor-in-Chief
| Reprints

The Food and Drug Administration (FDA) has approved a new drug treatment to combat Methicillin-resistant Staphylococcus aureus, or MRSA, and other bacterial skin infections.

The drug, to be marketed as Dalvance (dalbavancin), is the first intravenous treatment that is administered once a week instead of once or twice a day, noted an announcement from Durata Therapeutics, the drug’s manufacturer.

The drug was the first to be labeled as a qualified infectious disease product, which made it eligible for expedited review under the Generating Antibiotics Incentives Now (GAIN) Act, passed by Congress in 2012 to help fast-track development of new antibiotics to combat the growing pool of drug-resistant microbes.

The drug is expected to hit the market later this year.

Memory Care Forum - Focus: Resident Care

Get the latest information on Resident Care, and attend other valuable sessions at this two-day event making education on the research, innovations, and program approaches to memory care a priority.

Philadelphia, May 23-24   |   San Diego, September 22-23